Federated Hermes, Inc. Fate Therapeutics Inc Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Federated Hermes, Inc. holds 553,100 shares of FATE stock, worth $929,208. This represents 0.0% of its overall portfolio holdings.

Number of Shares

553,100

Previous 1,031,505 46.38%

Holding current value

$929,208

Previous $3.38 Million 42.8%

% of portfolio

0.0%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$3.12 - $5.57 $1.49 Million - $2.66 Million	-478,405 Reduced 46.38%	553,100 $1.94 Million
Q2 2024 Aug 08, 2024	BUY	$3.26 - $7.08 $78,654 - $170,819	24,127 Added 2.4%	1,031,505 $3.38 Million
Q1 2024 May 14, 2024	SELL	$3.54 - $8.35 $2.98 Million - $7.03 Million	-842,494 Reduced 45.54%	1,007,378 $7.39 Million
Q4 2023 Jan 31, 2024	SELL	$1.65 - $3.94 $992,758 - $2.37 Million	-601,672 Reduced 24.54%	1,849,872 $6.92 Million
Q3 2023 Nov 13, 2023	SELL	$2.02 - $5.04 $35,865 - $89,485	-17,755 Reduced 0.72%	2,451,544 $5.2 Million
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $3.84 Million - $5.32 Million	806,978 Added 48.55%	2,469,299 $11.8 Million
Q1 2023 May 08, 2023	BUY	$4.24 - $11.12 $4.61 Million - $12.1 Million	1,086,805 Added 188.84%	1,662,321 $9.48 Million
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $4.44 Million - $10.7 Million	450,513 Added 360.4%	575,516 $5.81 Million
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $261,232 - $447,720	-12,416 Reduced 9.04%	125,003 $2.8 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $220,809 - $526,441	12,419 Added 9.94%	137,419 $3.41 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $5.03 Million - $6.92 Million	-74,785 Reduced 37.43%	125,000 $10.8 Million
Q1 2021 May 13, 2021	SELL	$72.16 - $117.4 $3.81 Million - $6.2 Million	-52,816 Reduced 20.91%	199,785 $16.5 Million
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $710,645 - $1.88 Million	-18,657 Reduced 6.88%	252,601 $23 Million
Q3 2020 Nov 12, 2020	SELL	$30.41 - $40.5 $2.88 Million - $3.84 Million	-94,794 Reduced 25.9%	271,258 $10.8 Million
Q2 2020 Aug 13, 2020	SELL	$20.21 - $35.23 $1.99 Million - $3.47 Million	-98,462 Reduced 21.2%	366,052 $12.6 Million
Q1 2020 May 13, 2020	BUY	$17.28 - $31.88 $8.03 Million - $14.8 Million	464,514 New	464,514 $10.3 Million
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $3.67 Million - $5.34 Million	-237,317 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $3.46 Million - $4.53 Million	-221,552 Reduced 48.28%	237,317 $4.82 Million
Q1 2019 May 10, 2019	BUY	$13.15 - $18.71 $1.43 Million - $2.04 Million	109,118 Added 31.2%	458,869 $8.06 Million
Q4 2018 Feb 13, 2019	BUY	$11.48 - $16.98 $1.14 Million - $1.69 Million	99,287 Added 39.64%	349,751 $4.49 Million
Q3 2018 Nov 13, 2018	BUY	$8.75 - $16.29 $2.19 Million - $4.08 Million	250,464 New	250,464 $4.08 Million
Q2 2018 Aug 10, 2018	SELL	$9.16 - $13.48 $925 - $1,361	-101 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$6.3 - $13.77 $2,211 - $4,833	-351 Reduced 77.65%	101 $1,000
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $1,780 - $3,001	452	452 $0

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Fate Therapeutics Inc Transaction History